Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,733 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chemotherapy Clear all
Terminated Not applicable Interventional Results available

Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN)

NCT06324344
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Pain, Neuropathy
Interventions
High-Dose TENS, Low-Dose TENS
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Jul 22, 2026, 4:43 AM EDT
Suspended Phase 2 Interventional

Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients

NCT00004999
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
46
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Efficacy of Ramelteon on Transient Insomnia in Healthy Adults

NCT00671398
View directory record Official record
Conditions
Transient Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 64 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
12
States / cities
Palm Springs, California • San Diego, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Not applicable Interventional

Acupressure in Preventing Nausea and Vomiting in Young Cancer Patients Receiving Chemotherapy

NCT00310063
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
acupressure therapy, sham intervention
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Jul 22, 2026, 4:43 AM EDT
Suspended Phase 1 Interventional

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

NCT03710421
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
CS1-CAR T Therapy, Cyclophosphamide, Fludarabine, Leukapheresis
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 4:43 AM EDT
Active, not recruiting Phase 2 Interventional

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT05500092
View directory record Official record
Conditions
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions
Nivolumab, (8gy x 3), Platinum Doublet
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

Perioperative Therapy for Resectable Pancreatic Cancer

NCT00609336
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
gemcitabine hydrochloride, docetaxel, capecitabine, intensity-modulated radiation therapy, oxaliplatin, pancreatic surgical procedure, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Phase 2 Interventional

A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments

NCT00006211
View directory record Official record
Conditions
HIV Infections
Interventions
Capravirine, Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Music Therapy at TMH Infusion Center

NCT06450626
View directory record Official record
Conditions
Music Therapy
Interventions
Listening Music Intervention
Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Phase 1Phase 2 Interventional

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

NCT00066885
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
calcitriol + docetaxel
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
11
States / cities
Berkeley, California • Vallejo, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2007 · Synced Jul 22, 2026, 4:43 AM EDT
Completed No phase listed Observational Results available

Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

NCT01632267
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Not listed
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Phase 3 Interventional

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

NCT00002707
View directory record Official record
Conditions
Breast Cancer
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, Tamoxifen
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Enrollment
2,411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
134
States / cities
Huntsville, Alabama • Phoenix, Arizona • Greenbrae, California + 115 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Jul 22, 2026, 4:43 AM EDT
Recruiting Phase 3 Interventional

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336
View directory record Official record
Conditions
Endometrial Cancer, Malignant Solid Tumour
Interventions
Puxitatug Samrotecan, Doxorubicin, Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
68
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 4:43 AM EDT
Active, not recruiting Phase 2 Interventional

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

NCT04367311
View directory record Official record
Conditions
Lung Cancer, NSCLC
Interventions
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Drug
Lead sponsor
Nasser Hanna
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Chicago, Illinois • Indianapolis, Indiana • Berkeley Heights, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 22, 2026, 4:43 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions
AFNT-211
Drug
Lead sponsor
Affini-T Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 22, 2026, 4:43 AM EDT
Not listed Phase 1 Interventional

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

NCT00002616
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, filgrastim, carboplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
Up to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 22, 2026, 4:43 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer

NCT00036985
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, conventional surgery, neoadjuvant therapy, thermal ablation therapy
Drug · Procedure
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Coral Springs, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Jul 22, 2026, 4:43 AM EDT
Withdrawn Phase 2 Interventional

Preventing Frequent Sinus Infections in HIV-Infected Patients

NCT00000752
View directory record Official record
Conditions
HIV Infections, Sinusitis
Interventions
Pseudoephedrine hydrochloride, Guaifenesin, Cefuroxime axetil, Beclomethasone dipropionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Phase 2 Interventional

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

NCT00540358
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine/carboplatin, iniparib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
18
States / cities
Birmingham, Alabama • Denver, Colorado • Torrington, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Jul 22, 2026, 4:43 AM EDT
Suspended Not applicable Interventional

Quality of Life in Pediatric Patients With Acute Lymphoblastic Leukemia Receiving Maintenance Chemotherapy

NCT03132948
View directory record Official record
Conditions
Quality of Life
Interventions
Physical Activity
Behavioral
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2031
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Phase 2 Interventional

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

NCT00257478
View directory record Official record
Conditions
Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate
Interventions
YM155
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
7
States / cities
Tuscon, Arizona • Los Angeles, California • Coeur d'Alene, Idaho + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-105 in Healthy Adults

NCT04964258
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-105-a, TAK-105-a Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Tempe, Arizona • Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Jul 22, 2026, 4:43 AM EDT
Terminated Phase 1 Interventional

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

NCT02476955
View directory record Official record
Conditions
Solid Tumors, Ovarian Cancer, Endometrial Cancer
Interventions
ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Jul 22, 2026, 4:43 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

NCT00354835
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Localized Childhood Soft Tissue Sarcoma, Rhabdomyosarcoma, Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
Interventions
Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Vincristine Sulfate
Drug · Biological · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
196
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 142 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Jul 22, 2026, 4:43 AM EDT